Coya Therapeutics, Inc. (COYA)

↓ Download CSV

CIK 0001835022 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Coya Therapeutics, Inc. reported revenue of $7.95M, up 123.6% from the prior year. The company ran a net loss, with a net margin of -267.1%. It held $49.95M in total assets against $6.92M in total liabilities.

Key ratios (FY2025)

-283.9%
Operating margin
-267.1%
Net margin
-49.3%
Return on equity
+123.6%
Revenue growth (YoY)
Metric (FY)202520242023202220212020
Revenue$7.95M$3.55M$6.00M$0
Operating Income-$22.56M-$17.25M-$7.90M-$9.81M-$4.87M
Net Income-$21.23M-$14.88M-$7.99M-$12.24M-$4.89M
EPS (Diluted)$-1.27$-0.98$-0.79$-4.73$-1.89
Total Assets$49.95M$44.35M$41.26M$8.40M$4.79M
Total Liabilities$6.92M$4.77M$5.63M$16.79M$1.15M
Shareholders' Equity$43.03M$39.58M$35.64M-$8.39M$3.64M$8.30M
Cash & Equivalents$46.82M$38.34M$32.63M$5.93M$4.34M
Operating Cash Flow-$10.74M-$10.29M-$11.19M-$7.24M-$3.90M
Shares Outstanding20.93M16.71M14.41M2.59M2.59M